Clinical trial
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI…
NCT00243087 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00243087 |
|---|---|
| Title | Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL) |
| Official title | An Open Phase I Single Dose Escalation Study of BI 2536 Administered Intravenously in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | BI 2536 |
| Enrollment | 41 |
| Start date | Jul 1, 2005 |
| Primary completion | Aug 1, 2008 |
| First posted | Oct 21, 2005 |
| Last update posted | Dec 20, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: